Mylan Confirms First-to-File Patent Challenge Relating to Vimpat(R)

     Mylan Confirms First-to-File Patent Challenge Relating to Vimpat(R)

-Expects to be eligible for 180 days of marketing exclusivity-

PR Newswire

PITTSBURGH, July 15, 2013

PITTSBURGH, July 15, 2013 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
confirmed that the company has been sued by UCB, Inc., UCB Pharma GMBH,
Research Corporation Technologies, Inc. and Harris FRC Corporation in
connection with the filing of an Abbreviated New Drug Application (ANDA) with
the U.S. Food and Drug Administration (FDA) for Lacosamide Tablets, 50 mg, 100
mg, 150 mg and 200 mg. This product is the generic version of Vimpat^®, which
is approved as an adjunctive therapy to treat partial-onset seizures of people
diagnosed with epilepsy aged 17 years and older.

Mylan believes it is one of the first companies to have filed a substantially
complete ANDA containing a Paragraph IV certification for this product and
expects to be eligible for 180 days of marketing exclusivity upon final FDA
approval. The plaintiffs have filed a lawsuit against Mylan and several other
ANDA filers in the United States District Court for the District of Delaware.

For the 12 months ending March 31, 2013, Vimpat^® had U.S. sales of
approximately $338 million, according to IMS Health.

Currently, Mylan has 173 ANDAs pending FDA approval representing $82.9 billion
in annual sales, according to IMS Health. Thirty-five of these pending ANDAs
are potential first-to-file opportunities, representing $22.6 billion in
annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS
Health.

This press release includes statements that constitute "forward-looking
statements," including with regard to the expected first-to-file status and
pending litigation. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: the use of legal, regulatory and
legislative strategies by competitors or other third parties to delay or
prevent product introductions; risks inherent in legal and regulatory
processes; and the other risks detailed in the company's filings with the
Securities and Exchange Commission. The company undertakes no obligation to
update these statements for revisions or changes after the date of this
release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), 724.514.1968, Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.